Celator R Pharmaceuticals Announces Positive Phase 2 Results For CPX-1 In Treatment Of Colorectal Cancer

Celator Pharmaceuticals reported positive results from its CPX-1 Phase 2 clinical trial in patients with advanced colorectal cancer. CPX-1 is a liposomal formulation of irinotecan and floxuridine, based on the company's proprietary CombiPlex(TM) technology.

Newly Published Study Shows OPKO's SiRNA Bevasiranib Is Taken Up By Target Tissues In The Eye

OPKO Health, Inc. (Amex: OPK) announced that a study published in the peer-reviewed journal Molecular Vision demonstrates that bevasiranib, its siRNA (small interfering RNA) agent is distributed throughout the eye, including extensive uptake into the retina.

BioServe Unveils SNPlates TM For Economical Genetic Case-Control Studies - Ready-Made Case-Control Studies On A Plate

BioServe introduced SNPlates, a product-line that promises to significantly reduce both the cost and complexity of how disease case-control studies are currently conducted. Leveraging BioServe's Global Repository(R) of human biological samples, SNPlates are comprised of DNA consisting of 180 cases and 180 matched controls in ready-made 96 and 384 well plate formats with comprehensive, de-identified covariate data such as age, gender, diet, body mass index (BMI) and race.

Paclitaxel Poliglumex OPAXIO TM Capecitabine Regimen Well Tolerated And Active In Metastatic Breast Cancer

At the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO), data were presented from a phase II investigator-sponsored trial paclitaxel poliglumex (OPAXIO(TM), CT-2103) in combination with capecitabine in first-line treatment of patients with metastatic breast cancer (MBC).

Lung Cancer Alliance Hails Announcement Of New Erbitux R Data

Lung Cancer Alliance (LCA) hailed the release of promising data from the pivotal Phase III First Line in Lung Cancer with Erbitux(R) (FLEX) Study. The data, presented at the American Society of Clinical Oncology (ASCO), showed a significant increase in overall survival in the first line treatment of patients with non-small cell lung cancer (NSCLC).

Peregrine Pharmaceuticals Presents Promising Phase I Data At ASCO And Provides Clinical Update On Its Phase II Bavituximab Breast Cancer Study

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) announced that results from a Phase I clinical trial of its lead anti-phosphatidylserine (anti-PS) antibody bavituximab in combination with chemotherapy in patients with advanced cancer were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Early Data Presented At ASCO Show Potential Of RAD001 To Enhance Efficacy Of, And Overcome Resistance To, Breast Cancer Treatments

Early proof-of-concept studies presented show RAD001 (everolimus) may offer a novel treatment strategy for breast cancer by enhancing the efficacy of, and overcoming resistance to, several commonly used breast cancer treatments. Findings from a Phase II study show that RAD001 enhances tumor shrinkage when given in combination with letrozole tablets (Femara(R)) to postmenopausal women with newly diagnosed estrogen receptor-positive (ER+) breast cancer.

Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 PEG-irinotecan

Nektar Therapeutics (Nasdaq: NKTR) announced an expanded Phase 2 development plan for NKTR-102 (PEG-irinotecan). The company will target newly-characterized colorectal cancer patients with K-Ras mutated gene status in its Phase 2 study in advanced colorectal cancer.

Simple Kidney Protein Test Speeds Improves The Diagnosis Of Injured Kidneys

Walk into any emergency department complaining of chest pain and you are likely to have blood drawn. Within hours it should be clear whether you've had a heart attack, based on enzyme levels in your blood and whether those levels reveal the tissue damage normally associated with a heart attack or other major cardiac event.

Jazz Pharmaceuticals, Inc. Completes Enrollment In First Of Two Phase III Clinical Trials Of Sodium Oxybate To Treat Fibromyalgia

Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced completion of enrollment in the first of two Phase III pivotal clinical trials of JZP-6 (sodium oxybate) for the treatment of fibromyalgia. "Completion of enrollment in this trial is a key milestone in the JZP-6 program.